Introduction
Insulin and glucagon are the founding peptide hormones of modern endocrinology. Their opposing actions in blood glucose regulation, their structural relationship as products of pancreatic islet cells, and their central roles in diabetes — the most common metabolic disease — make them the most clinically important peptide hormones in medicine. Understanding their biology provides essential context for research with GLP-1 and other metabolic peptides that modulate the islet axis.
Insulin: Structure and Production
Insulin is a 51-amino acid peptide produced by beta cells of the pancreatic islets of Langerhans. It is synthesized as preproinsulin, processed to proinsulin, and cleaved to produce the active insulin molecule — two chains (A chain, 21 amino acids; B chain, 30 amino acids) connected by two disulfide bridges. C-peptide, the connecting peptide removed during processing, is co-secreted with insulin and serves as a clinical marker of endogenous insulin production. Insulin was the first protein sequenced (Sanger, 1955) and the first commercially produced recombinant pharmaceutical protein.
Insulin Mechanism
Insulin acts through the insulin receptor — a receptor tyrosine kinase. Binding triggers autophosphorylation and recruitment of insulin receptor substrate (IRS) proteins, activating PI3K-Akt and MAPK pathways. Akt activation promotes GLUT4 glucose transporter translocation to the plasma membrane in muscle and adipose cells, enabling glucose uptake. Akt also activates glycogen synthase (storing glucose as glycogen), promotes protein synthesis through mTOR, and inhibits lipolysis. These coordinated actions reduce blood glucose and promote anabolic metabolism.
Glucagon: The Counter-Regulatory Hormone
Glucagon is a 29-amino acid peptide produced by alpha cells of the pancreatic islets. It is structurally related to GLP-1, GLP-2, GIP, secretin, and VIP — all members of the glucagon superfamily. Glucagon is secreted in response to low blood glucose and acts primarily in the liver to stimulate glycogenolysis (breakdown of glycogen to glucose) and gluconeogenesis (synthesis of glucose from non-carbohydrate precursors), raising blood glucose. Glucagon also stimulates lipolysis in adipose tissue and has positive chronotropic and inotropic cardiac effects.
The Islet Paracrine Axis
Beta cells and alpha cells within pancreatic islets are not independent — they communicate through paracrine signaling. Insulin secreted by beta cells suppresses glucagon secretion from adjacent alpha cells. Glucagon stimulates insulin secretion from beta cells. Somatostatin, secreted by delta cells, inhibits both insulin and glucagon release. This islet paracrine network creates a tightly regulated local control system that fine-tunes the insulin-glucagon ratio in response to glucose concentrations.
GLP-1’s Role in Islet Regulation
GLP-1 — the most important incretin hormone — acts on both islet cell types. GLP-1 receptor activation on beta cells enhances glucose-stimulated insulin secretion. GLP-1 receptor activation on alpha cells suppresses glucagon secretion in a glucose-dependent manner. This dual action on both islet cell types — enhancing insulin while suppressing glucagon — provides comprehensive prandial glucose control and explains much of the clinical efficacy of GLP-1 receptor agonists. Understanding the islet paracrine axis illuminates why GLP-1-based therapies are so effective: they simultaneously fix both sides of the insulin-glucagon imbalance characteristic of type 2 diabetes.
Research Tools for Islet Biology
Isolated pancreatic islets, MIN6 and INS-1 beta cell lines, and transgenic reporter mice are the primary tools for islet biology research. Peptide tools used in islet research include: native GLP-1 for acute secretion studies, GLP-1 analogues for receptor pharmacology, glucagon for counterregulation research, and exendin 9-39 (a GLP-1 receptor antagonist) for mechanistic dissection of GLP-1-mediated effects.
Conclusion
Insulin and glucagon define the islet paracrine axis that regulates blood glucose homeostasis through opposing peptide hormone actions. Their structural relationship within the glucagon superfamily, their regulation by the islet paracrine network, and their interaction with GLP-1 incretin signaling make them central to understanding metabolic peptide research. This biology underpins the entire field of incretin pharmacology that has produced the most successful peptide therapeutic programs in history.